ASP 3662

Drug Profile

ASP 3662

Alternative Names: ASP-3662

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Astellas Pharma
  • Class Analgesics; Antidementias
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Diabetic neuropathies

Most Recent Events

  • 31 Jul 2017 Discontinued - Phase-II for Alzheimer's disease in USA (PO) (Astellas pipeline, July 2017)
  • 31 Jan 2017 Phase-II clinical trials in Alzheimer's disease in USA (PO) (Astellas Pharma pipeline, January 2017)
  • 26 Sep 2016 Updated pharmacodynamics data from preclinical studies in Diabetic neuropathies presented at the 16th World Congress of Pain-2016 (WCP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top